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The standard deviations for ‘last HbA1c measurement’ in
mmol/mol were miscalculated in Table 1 of this paper. The
corrected table is reproduced here. The changes do not affect
the interpretation of any of the data or the overall messages
of the paper.
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Table 1 Clinical profiles, care processes and self-monitoring in participants with type 2 diabetes at enrolment between 2005 and 2017
















Age, years (SD) 58.1 (11.5) 58.2 (11.8) 57.7 (11.8) 58.4 (11.9) 57.6 (11.2) 57.3 (10.7) 57.2 (11.1)
Female sex, n (%) 5130 (51.9) 8736 (52.2) 6458 (54.1) 2882 (54.3) 5117 (53.3) 3048 (55.6) 3291 (52.2)
Weight, kg (SD) 71.6 (14.9) 75.4 (16.0) 76.7 (16.2) 78.9 (16.5) 80.6 (16.2) 82.6 (16.7) 82.0 (16.7)
Disease duration, years 8.3 (7.1) 8.6 (7.8) 8.8 (7.7) 9.1 (8.1) 8.7 (7.3) 9.3 (7.1) 9.8 (7.4)
BMI, kg/m2 (SD) 27.1 (4.8) 28.5 (5.3) 29.0 (5.5) 29.8 (5.5) 29.6 (5.5) 30.2 (5.7) 29.8 (5.5)
Hypertension, n (%) 6029 (60.9) 10,681 (62.5) 7422 (61.0) 3254 (61.1) 6315 (66.0) 3623 (66.4) 4166 (66.2)
Dyslipidaemia, n (%) 4844 (49.3) 9609 (60.2) 7267 (62.5) 3485 (67.2) 5855 (63.4) 3449 (64.8) 3970 (68.9)
Last HbA1c measurement,
mmol/mol (SD)
61.5 (19.5) 63.2 (21.1) 62.3 (21.3) 62.6 (20.2) 64.4 (21.0) 64.1 (19.5) 64.6 (20.7)
Last HbA1c measurement,
% (SD)
7.8 (1.8) 7.9 (1.9) 7.9 (2.0) 7.9 (1.9) 8.0 (1.9) 8.0 (1.8) 8.1 (1.9)
HbA1c testing, n (%) 6116 (61.8) 12,492 (76.5) 9217 (80.4) 4401 (85.5) 8399 (90.0) 4952 (92.1) 5719 (92.9)
Frequency of testing of
HbA1c during past year
1.6 (1.2) 2.2 (1.4) 2.3 (1.4) 2.2 (1.5) 2.2 (1.8) 2.2 (2.0) 2.2 (1.7)
Mean values are presented unless otherwise stated
Percentages were calculated for patients with available data; these varied by each category/wave
Hypertension and dyslipidaemia were defined (yes/no) according to the attending physician
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